Enanta Pharmaceuticals Inc (ENTA) — 8-K Filings

8-K Filings (16)

• Enanta Pharma Files 8-K for Undisclosed 'Other Event' — Mar 26, 2026
  Enanta Pharmaceuticals Inc. filed an 8-K on March 26, 2026, reporting an "Other Event" under Item 8.01 related to its period of report ending March 20, 2026. Wh
• 8-K Filing — Nov 17, 2025
• Enanta Pharmaceuticals Files 8-K — Oct 1, 2025 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on October 1, 2025, reporting events as of September 30, 2025. The filing primarily concerns financial statements and
• Enanta Pharmaceuticals Files 8-K Report — Sep 29, 2025 Risk: low
  On September 29, 2025, Enanta Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial st
• Enanta Pharmaceuticals Announces Executive and Director Changes — Aug 27, 2025 Risk: medium
  Enanta Pharmaceuticals, Inc. announced on August 26, 2025, changes in its executive and director roles. The company appointed Dr. Sarah Johnson as Chief Medical
• Enanta Pharmaceuticals Files 8-K — Aug 20, 2025 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on August 20, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements a
• Enanta Pharmaceuticals Files 8-K on Financials — Aug 11, 2025 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on August 11, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements an
• Enanta Pharmaceuticals Files 8-K — May 12, 2025 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and e
• Enanta Pharmaceuticals Files 8-K on Officer/Director Changes — Mar 17, 2025 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on March 17, 2025, reporting events as of March 13, 2025. The filing covers the departure of directors or certain offi
• Enanta Pharmaceuticals Files 8-K on Financials — Feb 10, 2025 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on February 10, 2025, reporting on its results of operations and financial condition. The filing also includes financi
• Enanta Pharmaceuticals Files 8-K Report — Dec 9, 2024 Risk: low
  On December 9, 2024, Enanta Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial stat
• Enanta Pharmaceuticals Files 8-K — Nov 25, 2024 Risk: low
  On November 25, 2024, Enanta Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditio
• Enanta Pharmaceuticals Files 8-K — Aug 5, 2024 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Enanta Pharmaceuticals Files 8-K — May 6, 2024 Risk: low
  Enanta Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and ex
• Enanta Pharma Appoints New CMO and Head of Research — Mar 12, 2024 Risk: low
  Enanta Pharmaceuticals, Inc. announced on March 6, 2024, the appointment of Dr. Jay L. D. Weinstein as Chief Medical Officer and Dr. Sarah J. De Bruin as Senior
• Enanta Pharma Files 8-K on Financial Results & Operations — Feb 7, 2024
  Enanta Pharmaceuticals, Inc. filed an 8-K on February 7, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Ex

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX